Cargando…
MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
BACKGROUND: Though long recognized as a master regulator of cell proliferation across a wide range of cancers, Myc has proven elusive to direct therapeutic targeting. The CDK9-containing PTEFb, complexed with either BRD4 or SEC, facilitates Myc-driven transcriptional programs and is necessary for su...
Autores principales: | Madhavan, Krishna, Walker, Faye, Wang, Dong, Sobral, Lays Martin, Balakrishnan, Ilango, Pierce, Angela, Serkova, Natalie, Foreman, Nicholas, Venkataraman, Sujatha, Vibhakar, Rajeev, Dahl, Nathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164830/ http://dx.doi.org/10.1093/neuonc/noac079.402 |
Ejemplares similares
-
MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023) -
MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022) -
MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022) -
MEDB-70. Metabolism mediated radiation resistance in MYC-driven Medulloblastoma
por: Veo, Bethany, et al.
Publicado: (2022) -
MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture
por: Willard, Nicholas, et al.
Publicado: (2022)